Schrodinger Partners with Eli Lilly to Launch AI Drug Design Platform TuneLab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Newsfilter
- Collaborative Innovation: Schrodinger's partnership with Eli Lilly integrates Lilly's AI platform TuneLab into its LiveDesign software, enabling biotech companies to directly access this advanced tool, thereby accelerating drug development processes.
- Technological Advantage: By incorporating TuneLab into LiveDesign, chemists can more effectively design compounds and predict drug behavior in the body, enhancing the efficiency and accuracy of drug research and development.
- Market Demand: With the FDA pushing to reduce animal testing, the increasing adoption of AI by drug developers is expected to meet the urgent market demand for faster and more cost-effective drug discovery, making this collaboration timely.
- Client Expansion: Existing LiveDesign clients will gain access to TuneLab in Q1 of this year, while new users will start using it in Q2, which is anticipated to attract more biotech companies and drive diversity and speed in drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1038.270
Low
950.00
Averages
1192
High
1500
Current: 1038.270
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Innovation and Growth Prospects
- Strong Clinical Execution: Eli Lilly achieved positive outcomes in nearly all R&D key events in 2025, showcasing exceptional performance in diabetes and weight loss medications, which is expected to further drive market share and revenue growth in the future.
- Cancer Drug Progress: The company's cancer medication, Jaypirca, excelled in a phase 3 trial and is on track for label expansions, which will provide new revenue streams and enhance its competitiveness in oncology treatment.
- AI Investment: Eli Lilly is investing in building the industry's largest AI supercomputer to accelerate drug development, which is expected to significantly improve clinical trial success rates and bolster the company's innovative standing and market leadership in the pharmaceutical sector.
- Robust Financial Performance: The company continues to report strong financial results, boasts a rich product pipeline, and rewards shareholders through increasing dividends and share buybacks, demonstrating its diversified growth potential beyond diabetes and weight loss markets.
See More
Eli Lilly Reports Positive Results for Retevmo in NSCLC Trial
- Trial Success: The LIBRETTO-432 trial demonstrated that Retevmo (selpercatinib) as adjuvant therapy significantly improved event-free survival (EFS) in early-stage RET fusion-positive non-small cell lung cancer (NSCLC) patients, indicating its potential value and likely enhancing market acceptance.
- Survival Trends Favorable: Although overall survival results were immature at the time of analysis, preliminary data showed a favorable trend for Retevmo, highlighting its importance in early treatment and potentially encouraging more patients to undergo genomic testing for optimized therapy.
- Patient Recruitment: The LIBRETTO-432 trial enrolled 151 patients randomized 1:1 to receive either Retevmo or placebo, ensuring the reliability and clinical applicability of the results, further validating the use of targeted therapies in lung cancer.
- Future Outlook: Eli Lilly plans to present detailed trial results at an upcoming medical congress and submit data to global health authorities, which is expected to accelerate the adoption of targeted therapies in early-stage NSCLC patients and promote the widespread use of genomic testing.
See More
Eli Lilly to Participate in TD Cowen's 46th Annual Health Care Conference
- Conference Participation: Eli Lilly will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026, where CFO Lucas Montarce will engage in a fireside chat at 3:10 PM Eastern Time, highlighting the company's latest advancements in healthcare.
- Live Webcast: The event will feature a live audio webcast available on Lilly's investor website, ensuring global investors can access real-time information, thereby enhancing transparency and investor confidence.
- Replay Availability: A replay of the presentation will be accessible on the same website for approximately 90 days, allowing investors who cannot attend live to catch up on important updates, thus improving communication efficiency between the company and its investors.
- Company Mission: Eli Lilly is committed to addressing global health challenges through innovations in biotechnology, chemistry, and genetic medicine, aiming to improve the quality of life for tens of millions, showcasing its leadership and social responsibility in the healthcare sector.
See More
Chai Discovery Secures $130 Million Funding at $1.3 Billion Valuation
- Funding Achievement: Chai Discovery completed a $130 million Series B funding round in 2024, achieving a valuation of $1.3 billion and securing its status as a unicorn, reflecting strong market confidence in its AI-driven drug development potential.
- Partnership Development: The company has established a partnership with pharmaceutical giant Eli Lilly, which will utilize Chai's AI models for multiple drug development projects, marking a significant advancement in the application of AI within the pharmaceutical industry.
- Technological Innovation: Chai Discovery is developing a computer-aided molecular design software aimed at increasing drug development success rates, with the success rate improving from 0.1% to 20% over the past year, showcasing rapid technological advancements and strong market demand.
- Founder's Background: Co-founder Joshua Meier has a rich background from OpenAI and Meta, providing extensive experience in AI and biotechnology, which lays a solid foundation for Chai Discovery's innovations and underscores its leadership position in AI drug development.
See More
Selpercatinib Shows Significant Improvement in Lung Cancer Outcomes
- Trial Success: Eli Lilly announced that selpercatinib demonstrated a significant improvement in event-free survival (EFS) for early-stage RET fusion-positive non-small cell lung cancer patients in the LIBRETTO-432 trial, providing strong clinical evidence for early intervention and potentially enhancing market acceptance of the drug.
- Patient Recruitment: The trial enrolled 151 patients randomized 1:1 to receive either selpercatinib or placebo, with results indicating that selpercatinib outperformed placebo in EFS, further validating the importance of genomic testing in early lung cancer diagnosis.
- Safety Profile: The safety profile of selpercatinib in LIBRETTO-432 was consistent with previous studies, with some patients experiencing hepatotoxicity and hypertension; however, the overall safety was manageable, laying a foundation for its clinical application.
- Future Outlook: Eli Lilly plans to present detailed results at an upcoming medical congress and submit data to global health authorities, which is expected to accelerate the adoption of genomic testing in early lung cancer patients and further promote the development of precision medicine.
See More
Eli Lilly Leverages AI to Transform Drug Development
- AI Platform Launch: Eli Lilly launched the TuneLab platform in September last year, allowing other drugmakers digital access to proprietary data on drug molecule performance, which saves significant time and money, enabling companies to focus on their best research projects.
- Major Investment Partnership: Eli Lilly partnered with Nvidia, committing $1 billion to build a supercomputer aimed at deepening disease understanding and advancing drug development, marking a significant step in the company's AI drug development efforts.
- Huge Market Potential: According to Straits Research, the AI-powered drug discovery industry is expected to grow at an annual rate of 30% through 2034, reaching over $20 billion, providing Eli Lilly with substantial future revenue opportunities.
- Increased Collaboration Opportunities: By owning a powerful drug development platform, Eli Lilly can not only optimize its own research but also establish partnerships with smaller pharmaceutical companies, helping them bring new drugs to market and enhancing its competitive edge.
See More
Eli Lilly's Innovation and Growth Prospects
- Strong Clinical Execution: Eli Lilly achieved positive outcomes in nearly all R&D key events in 2025, showcasing exceptional performance in diabetes and weight loss medications, which is expected to further drive market share and revenue growth in the future.
- Cancer Drug Progress: The company's cancer medication, Jaypirca, excelled in a phase 3 trial and is on track for label expansions, which will provide new revenue streams and enhance its competitiveness in oncology treatment.
- AI Investment: Eli Lilly is investing in building the industry's largest AI supercomputer to accelerate drug development, which is expected to significantly improve clinical trial success rates and bolster the company's innovative standing and market leadership in the pharmaceutical sector.
- Robust Financial Performance: The company continues to report strong financial results, boasts a rich product pipeline, and rewards shareholders through increasing dividends and share buybacks, demonstrating its diversified growth potential beyond diabetes and weight loss markets.
See More
Eli Lilly Reports Positive Results for Retevmo in NSCLC Trial
- Trial Success: The LIBRETTO-432 trial demonstrated that Retevmo (selpercatinib) as adjuvant therapy significantly improved event-free survival (EFS) in early-stage RET fusion-positive non-small cell lung cancer (NSCLC) patients, indicating its potential value and likely enhancing market acceptance.
- Survival Trends Favorable: Although overall survival results were immature at the time of analysis, preliminary data showed a favorable trend for Retevmo, highlighting its importance in early treatment and potentially encouraging more patients to undergo genomic testing for optimized therapy.
- Patient Recruitment: The LIBRETTO-432 trial enrolled 151 patients randomized 1:1 to receive either Retevmo or placebo, ensuring the reliability and clinical applicability of the results, further validating the use of targeted therapies in lung cancer.
- Future Outlook: Eli Lilly plans to present detailed trial results at an upcoming medical congress and submit data to global health authorities, which is expected to accelerate the adoption of targeted therapies in early-stage NSCLC patients and promote the widespread use of genomic testing.
See More
Eli Lilly to Participate in TD Cowen's 46th Annual Health Care Conference
- Conference Participation: Eli Lilly will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026, where CFO Lucas Montarce will engage in a fireside chat at 3:10 PM Eastern Time, highlighting the company's latest advancements in healthcare.
- Live Webcast: The event will feature a live audio webcast available on Lilly's investor website, ensuring global investors can access real-time information, thereby enhancing transparency and investor confidence.
- Replay Availability: A replay of the presentation will be accessible on the same website for approximately 90 days, allowing investors who cannot attend live to catch up on important updates, thus improving communication efficiency between the company and its investors.
- Company Mission: Eli Lilly is committed to addressing global health challenges through innovations in biotechnology, chemistry, and genetic medicine, aiming to improve the quality of life for tens of millions, showcasing its leadership and social responsibility in the healthcare sector.
See More
Chai Discovery Secures $130 Million Funding at $1.3 Billion Valuation
- Funding Achievement: Chai Discovery completed a $130 million Series B funding round in 2024, achieving a valuation of $1.3 billion and securing its status as a unicorn, reflecting strong market confidence in its AI-driven drug development potential.
- Partnership Development: The company has established a partnership with pharmaceutical giant Eli Lilly, which will utilize Chai's AI models for multiple drug development projects, marking a significant advancement in the application of AI within the pharmaceutical industry.
- Technological Innovation: Chai Discovery is developing a computer-aided molecular design software aimed at increasing drug development success rates, with the success rate improving from 0.1% to 20% over the past year, showcasing rapid technological advancements and strong market demand.
- Founder's Background: Co-founder Joshua Meier has a rich background from OpenAI and Meta, providing extensive experience in AI and biotechnology, which lays a solid foundation for Chai Discovery's innovations and underscores its leadership position in AI drug development.
See More
Selpercatinib Shows Significant Improvement in Lung Cancer Outcomes
- Trial Success: Eli Lilly announced that selpercatinib demonstrated a significant improvement in event-free survival (EFS) for early-stage RET fusion-positive non-small cell lung cancer patients in the LIBRETTO-432 trial, providing strong clinical evidence for early intervention and potentially enhancing market acceptance of the drug.
- Patient Recruitment: The trial enrolled 151 patients randomized 1:1 to receive either selpercatinib or placebo, with results indicating that selpercatinib outperformed placebo in EFS, further validating the importance of genomic testing in early lung cancer diagnosis.
- Safety Profile: The safety profile of selpercatinib in LIBRETTO-432 was consistent with previous studies, with some patients experiencing hepatotoxicity and hypertension; however, the overall safety was manageable, laying a foundation for its clinical application.
- Future Outlook: Eli Lilly plans to present detailed results at an upcoming medical congress and submit data to global health authorities, which is expected to accelerate the adoption of genomic testing in early lung cancer patients and further promote the development of precision medicine.
See More
Eli Lilly Leverages AI to Transform Drug Development
- AI Platform Launch: Eli Lilly launched the TuneLab platform in September last year, allowing other drugmakers digital access to proprietary data on drug molecule performance, which saves significant time and money, enabling companies to focus on their best research projects.
- Major Investment Partnership: Eli Lilly partnered with Nvidia, committing $1 billion to build a supercomputer aimed at deepening disease understanding and advancing drug development, marking a significant step in the company's AI drug development efforts.
- Huge Market Potential: According to Straits Research, the AI-powered drug discovery industry is expected to grow at an annual rate of 30% through 2034, reaching over $20 billion, providing Eli Lilly with substantial future revenue opportunities.
- Increased Collaboration Opportunities: By owning a powerful drug development platform, Eli Lilly can not only optimize its own research but also establish partnerships with smaller pharmaceutical companies, helping them bring new drugs to market and enhancing its competitive edge.
See More
